Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down‐staging?

Francis Y. Yao, Nicholas Fidelman – 11 November 2015 – Down‐staging of hepatocellular carcinoma prior to liver transplantation (LT) has generated a lot of interest in recent years and has been identified in two recent national conferences on hepatocellular carcinoma as one of the priorities for research. Down‐staging is defined as reduction in the tumor burden using local regional therapy specifically to meet acceptable criteria for LT.

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

Julius M. Wilder, Lennox J. Jeffers, Natarajan Ravendhran, Mitchell L. Shiffman, John Poulos, Mark S. Sulkowski, Norman Gitlin, Kimberly Workowski, Yanni Zhu, Jenny C. Yang, Phillip S. Pang, John G. McHutchison, Andrew J. Muir, Charles Howell, Kris Kowdley, Nezam Afdhal, K. Rajender Reddy – 6 November 2015 – Black patients chronically infected with genotype 1 hepatitis C virus (HCV) have historically had lower rates of response to interferon‐based treatment than patients of other races.

Antibiotic prophylaxis in cirrhosis: Good and bad

Javier Fernández, Puneeta Tandon, Jose Mensa, Guadalupe Garcia‐Tsao – 3 November 2015 – Patients with cirrhosis, particularly those with decompensated cirrhosis, are at increased risk of bacterial infections that may further precipitate other liver decompensations including acute‐on‐chronic liver failure. Infections constitute the main cause of death in patients with advanced cirrhosis, and strategies to prevent them are essential.

Subscribe to